How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease

The availability of biologic therapies in inflammatory bowel disease (IBD) is increasing significantly. This represents more options to treat patients, but also more difficulties in choosing the therapies, especially in the context of bio-naïve patients. Most evidence of safety and efficacy came fro...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2022-02, Vol.11 (3), p.829
Main Authors: Laredo, Viviana, Gargallo-Puyuelo, Carla J, Gomollón, Fernando
Format: Article
Language:English
Subjects:
Biological products
Clinical medicine
Clinical trials
Drug dosages
Fistula
Infections
Inflammatory bowel disease
Patients
Psoriasis
Remission (Medicine)
Review
Steroids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The availability of biologic therapies in inflammatory bowel disease (IBD) is increasing significantly. This represents more options to treat patients, but also more difficulties in choosing the therapies, especially in the context of bio-naïve patients. Most evidence of safety and efficacy came from clinical trials comparing biologics with placebo, with a lack of head-to-head studies. Network meta-analysis of biologics and real-world studies have been developed to solve this problem. Despite the results of these studies, there are also other important factors to consider before choosing the biologic, such as patient preferences, comorbidities, genetics, and inflammatory markers. Given that resources are limited, another important aspect is the cost of biologic therapy, since biosimilars are widely available and have been demonstrated to be effective with a significant decrease in costs. In this review, we summarize the evidence comparing biologic therapy in both Crohn´s disease (CD) and ulcerative colitis (UC) in different clinical situations. We also briefly synthesize the evidence related to predictors of biologic response, as well as the biologic use in extraintestinal manifestations and the importance of the drug-related costs.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11030829